Negotiating and Structuring Strategic Alliances

Joe Zammit-Lucia;Chris Easley;Dechert London;David Schulman;

Publication

Article

June 15, 2002

BioPharm International

BioPharm International-06-01-2002

Volume15

Issue 6

Negotiating and Structuring Strategic Alliances

Author(s):

Joe Zammit-Lucia,Chris Easley

by David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Negotiating and Structuring Strategic Alliances

Finding Funding in Biotechnology: Keeping the Companies Alive

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

Unlocking the Value of R&D: Managing the Risks

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Negotiating and Structuring Strategic Alliances

Newsletter